Cell No. : Cell Name RCB1089 : ψCRIP-MFGmGM-CSF  update : 2023/08/08
Comment			Cartagena Protocol on Biosafety. Cell line producing MoMLV-derived retrovirus to express mouse GM-CSF. Long term culture results in decrease of virus production.
Comment from the depositor
Terms and conditions			There is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC.
Remarks
Order Form			Order Form(C-0005.pdf)   MTA(C-0007.pdf)   MTA(C-0007p.pdf)
			Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
	Basic information	Depositor	Hamada, Hirofumi
		Originator	Hamada, Hirofumi
		Year of deposit	1994
		Original cell	ψCRIP
		Animal	_mouse < Mammals
		Strain name	NIH Swiss
		Genus	Mus musculus
		Species	mus domesticus
		Age at sampling	embryo
		Tissue	embryo
		Classification	transformed
		Recombinant	recombinant
		Exogene	Amp^r, Mouse GM-CSF cDNA
		Recombinant virus	Yes
		Lifespan	infinite
		Morphology	fibroblast-like
		BSL	BSL2
		Cellosaurus(Expasy)	CVCL_T393
			deposit info	lot info
		Medium	Medium List
		Culture type		Adherent cells
		Culture medium		DMEM (low glucose) + 10% CS
		Antibiotics		Free
		Passage method		0.25% Trypsin
	Culture information	Passage ratio		1 : 4 split
		SC frequency		Subculture : 1-2 times/week, Medium Renewal : 2 times/week
		Temperature		37 ℃
		CO2 concentration		5 %
		Freeze medium		Medium + 10% DMSO
		Freezing method		Slow freezing
		Mycoplasma/Acholeplasma		(-)
		SSLP(mouse)		OK
		Isozyme		LD, NP
Reference information		Reference	3
		User's Publication	0

Top

Reference

3686  Wakimoto H, Abe J, Tsunoda R, Aoyagi M, Hirakawa K, Hamada H.  Intensified antitumor immunity by a cancer vaccine that produces granulocyte-macrophage colony-stimulating factor plus interleukin 4.  Cancer Res  1996  56(8):1828-33  PubMed ID: 8620500

2174  Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan, R C  Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.  Proc Natl Acad Sci U S A  1993  90:3539-43  PubMed ID: 8097319   DOI: 10.1073/pnas.90.8.3539

2172  Danos O, Mulligan, R C  Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges.  Proc Natl Acad Sci U S A  1988  85:6460-4  PubMed ID: 3413107   DOI: 10.1073/pnas.85.17.6460

Top

User's Publication